Global Non-Alcoholic Steatohepatitis Biomarkers Market Size By Type of Biomarker, By End User, By Geographic Scope And Forecast

Non-Alcoholic Steatohepatitis Biomarkers Market Size And Forecast

Non-Alcoholic Steatohepatitis Biomarkers Market size was valued at USD 1.49 Billion in 2023 and is projected to reach USD 6.55 Billion by 2030, growing at a CAGR of 23.5% during the forecast period 2024-2030.

The Non Alcoholic Steatohepatitis (NASH) Biomarkers Market encompasses a range of diagnostic and prognostic indicators used in the assessment and management of non-alcoholic fatty liver disease (NAFLD) progression towards NASH. These biomarkers aid in the early detection, monitoring, and stratification of patients at risk of developing NASH-related complications, such as liver fibrosis, cirrhosis, and hepatocellular carcinoma. As the prevalence of NAFLD continues to rise globally due to sedentary lifestyles, unhealthy dietary habits, and increasing obesity rates, the demand for accurate and reliable biomarkers for NASH diagnosis and disease progression monitoring is escalating.

Global Non-Alcoholic Steatohepatitis Biomarkers Market Drivers

The market drivers for the Non-Alcoholic Steatohepatitis Biomarkers Market can be influenced by various factors. These may include

• Growing Prevalence of NASH The increased incidence of obesity, type 2 diabetes, and metabolic syndrome is the main cause of the rising global health concern associated with non-alcoholic steatohepatitis. The need for biomarkers for early diagnosis, detection, and tracking of the disease’s course is increasing as the frequency of NASH rises.
• Rising Awareness and Diagnosis Rates As individuals and healthcare providers become more cognizant of the possible dangers connected to NASH, there has been a rise in the number of cases of screening and diagnosis. This fuels the need for biomarkers that can precisely identify and track the disease’s course.
• Lack of Effective therapy choices The majority of NASH medicines concentrate on treating underlying risk factors including diabetes and obesity in addition to controlling symptoms. At the moment, there aren’t many effective therapy choices for the condition. The necessity of biomarkers for identifying people at risk of developing NASH and tracking the disease’s course is highlighted by the absence of viable treatments.
• Regulatory Initiatives and Guidelines Regulatory bodies, like the European Medicines Agency (EMA) and the U.S. Food and medication Administration (FDA), are beginning to acknowledge the significance of biomarkers in NASH medication development and clinical trials. As a result, more money is now being spent on the study and creation of novel biomarkers for the detection and tracking of NASH.
• Technological Developments The identification and validation of novel biomarkers for NASH have been made possible by technological developments such as high-throughput omics technologies, molecular imaging methods, and bioinformatics. Biomarker assays have become more widely used in clinical practice because to the sensitivity, specificity, and repeatability that these technological improvements have brought about.
• Growing Interest in Precision Medicine In the field of hepatology, the idea of precision medicine—which attempts to customise medical care to each patient’s unique characteristics—has gained ground. Because they can predict treatment response and offer insights into disease heterogeneity, biomarkers are essential to the development of precision medicine approaches.
• Growing Research and Development Expenditures The creation of innovative NASH biomarkers is receiving significant funding from pharmaceutical companies, biotechnology businesses, and university research institutes. The potential business opportunity that NASH offers and the unmet demand for trustworthy diagnostic and prognostic tools are what motivate these efforts.

Global Non-Alcoholic Steatohepatitis Biomarkers Market Restraints

Several factors can act as restraints or challenges for the Non-Alcoholic Steatohepatitis Biomarkers Market. These may include

• Regulatory Difficulties In the healthcare sector, obtaining regulatory approval for biomarkers can be a drawn-out and challenging procedure. A major obstacle may be ensuring that biomarkers fulfil all legal requirements and receive FDA or other agency approval.
• Limited Knowledge and Understanding Patients’ and healthcare workers’ knowledge and comprehension of the importance of NASH biomarkers may be lacking. This may result in a reluctance to use biomarker testing in clinical practice and slower adoption rates.
• Cost and Reimbursement Issues Biomarker testing can be expensive, and there may be issues with healthcare payers paying for these tests. Healthcare providers might be reluctant to invest in biomarker testing if they don’t receive enough compensation, which would restrict market expansion.
• Competition from Alternative Diagnostic Tools Imaging methods (e.g., MRI, ultrasound), liver biopsies, and other alternative diagnostic tools are competitors for NASH biomarkers. Some medical professionals may still favour these conventional techniques, especially in areas where biomarker testing is not often offered or compensated.
• The diagnosis and treatment of non-alcoholic steatohepatitis (NASH) are intricate matters, involving a range of clinical manifestations and risk factors. For biomarkers to be clinically helpful, they must appropriately reflect the severity and development of the disease. It is still difficult to develop biomarkers that can efficiently stratify patients and direct therapy choices.
• Lack of Standardisation Biomarker assays and testing techniques may not be standardised, which could cause variations in results between laboratories and impede their broad use.
• Ethical and Privacy Issues The gathering, storing, and use of patient data may give rise to ethical and privacy issues with biomarker testing. Important factors to take into account are securing patient confidentiality and gaining informed consent for biomarker testing.
• Limited Clinical Evidence Although biomarker research has advanced, there may not be enough clinical data to support the usefulness and efficacy of particular NASH biomarkers in enhancing patient outcomes. In order to validate biomarkers and determine their clinical value, more thorough clinical trials are required.

Global Non-Alcoholic Steatohepatitis Biomarkers Market Segmentation Analysis

The Global Non-Alcoholic Steatohepatitis Biomarkers Market is Segmented on the basis Of Type Of Biomarker, End User, And Geography.

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type of Biomarker

• Serum biomarkers These are proteins or other molecules found in the blood that can indicate the presence or severity of NASH. Examples include liver enzymes, adipokines, and cytokines.
• Hepatic fibrosis biomarkers These biomarkers specifically assess the extent of scarring in the liver, a key feature of NASH progression. Examples include FibroTest and Enhanced Liver Fibrosis (ELF) score.
• Apoptosis biomarkers These biomarkers measure cell death in the liver, another indicator of NASH severity. Examples include Cytokeratin 18 (CK-18) and caspase-3.
• Oxidative stress biomarkers These biomarkers indicate the presence of free radicals and other harmful molecules that can damage liver cells. Examples include malondialdehyde (MDA) and 8-hydroxydeoxyguanosine (8-OHdG).
• Other biomarkers This category includes a variety of other potential biomarkers that are still under investigation, such as genetic markers and microRNAs.

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

• Pharmaceutical companies and CROs These companies use NASH biomarkers to develop and test new drugs for the treatment of NASH.
• Research institutes and academics These groups are involved in basic research on NASH and the development of new biomarkers.
• Hospitals & clinics Hospitals and clinics use NASH biomarkers to diagnose and monitor patients with NASH.
• Diagnostic centers These centers offer specialized tests for NASH biomarkers.
• Others This category includes other potential users of NASH biomarkers, such as insurance companies and government agencies.

Non-Alcoholic Steatohepatitis Biomarkers Market, By Geography

• North America Market conditions and demand in the United States, Canada, and Mexico.
• Europe Analysis of the Non-Alcoholic Steatohepatitis Biomarkers Market in European countries.
• Asia-Pacific Focusing on countries like China, India, Japan, South Korea, and others.
• Middle East and Africa Examining market dynamics in the Middle East and African regions.
• Latin America Covering market trends and developments in countries across Latin America.

Key Players

The major players in the Non-Alcoholic Steatohepatitis Biomarkers Market are

• Siemens Healthineers
• QIAGEN
• Genfit SA
• Metabolon Inc.
• NGM Biopharmaceuticals
• Perspectum Diagnostics
• Promethera Biosciences
• Glympse Bio
• Galectin Therapeutics
• Exalenz Bioscience

Report Scope

Analyst’s Take

In conclusion, the Non Alcoholic Steatohepatitis Biomarkers Market is poised for substantial growth in the coming years, driven by the escalating prevalence of NAFLD/NASH worldwide and the pressing need for non-invasive diagnostic and prognostic tools. Key market players are actively engaged in the development of novel biomarkers and diagnostic assays to meet the growing demand for effective NASH management solutions.

With advancements in omics technologies, such as genomics, proteomics, and metabolomics, coupled with increasing research investments and collaborations, the NASH biomarkers market is anticipated to witness significant expansion opportunities, offering promising prospects for stakeholders across the healthcare continuum.

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.